AIDS TREATMENT NEWS Issue No. 344, June 2, 2000
John S. James
The new vaccine will be taken orally, and could possibly cost less than $1 per dose to produce.
Several aspects of this technology are particularly important:
(1) There are many advantages to vaccines which work by delivering DNA which instructs cells to produce the specific proteins against which immunity is needed. But ordinarily DNA could not be taken orally because it would not reach the places it needs to go. The new technology uses a salmonella bacterium which has been genetically modified so that it does not cause disease--and also genetically modified so that it includes selected parts of HIV.
The salmonella bacterium "knows its way around the gut," and delivers the selected DNA directly to dendritic cells in the intestinal mucosa, which may be particularly effective for providing "mucosal immunity" to prevent HIV infection. This is important for blocking sexual transmission of the virus.
(2) This bacterium has plenty of room to carry added DNA, allowing great flexibility for modifications. If the first vaccine does not work, different versions can easily be made by trying other parts of the virus. And this vaccine can be customized for the different viral strains which cause epidemics in different parts of the world.
(3) The six standard children's vaccines cost less than $1 to produce (for all six), but $15 or more per person to deliver in developing countries, because of the need for sterile injection, specially trained health workers, etc. An oral medication should be much less expensive to deliver.
This vaccine is well along in its development, but clinical trials are still more than a year away. The first trials will take place in Baltimore and in Uganda, where the Ministry of Health is an active participant in this program. One trial will compare this vaccine head to head against an injected formulation which uses the same active ingredients but a very different delivery system--a vaccine also being funded by IAVI.
"The driving force for this decade-long effort [to create the new vaccine] has been the development of a simple delivery system for an HIV vaccine that can be administered without needles and that can be afforded by developing nations. Salmonella-DNA has these attributes built in from the start. We are extremely excited now to be able to evaluate this strategy in human volunteers," said Dr. George Lewis, Director of the IHV Division of Vaccine Research.
For more information on the Institute of Human Virology, see http://www.ihv.org ; for information on IAVI, see http://www.iavi.org
000602
ATN34402
Copyright © 2000 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .